Panteli Theocharous
About
In The Last Decade
Panteli Theocharous
16 papers receiving 488 citations
Peers
Comparison fields: 5 of 57
- Oncology 290
- Cancer Research 142
- Pathology and Forensic Medicine 130
- Molecular Biology 98
- Pulmonary and Respiratory Medicine 83
Countries citing papers authored by Panteli Theocharous
This map shows the geographic impact of Panteli Theocharous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Panteli Theocharous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Panteli Theocharous more than expected).
Fields of papers citing papers by Panteli Theocharous
This network shows the impact of papers produced by Panteli Theocharous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Panteli Theocharous. The network helps show where Panteli Theocharous may publish in the future.
Co-authorship network of co-authors of Panteli Theocharous
This figure shows the co-authorship network connecting the top 25 collaborators of Panteli Theocharous. A scholar is included among the top collaborators of Panteli Theocharous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Panteli Theocharous. Panteli Theocharous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 4 | |
| 4 | 23 | |
| 5 | 1 | |
| 6 | 17 | |
| 7 | FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation | 1 |
| 8 | 81 | |
| 9 | 2 | |
| 10 | 11 | |
| 11 | 9 | |
| 12 | Characterization of three pairs of prostate cells lines derived from tumor and adjacent normal tissues | 2 |
| 13 | Derivation and initial characterization of three new prostate cancer cell lines and three new immortalized normal prostate epithelial cell lines | 1 |
| 14 | 53 | |
| 15 | 231 | |
| 16 | 9 | |
| 17 | 2 | |
| 18 | 56 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.